Bulletin
Investor Alert

New York Markets Open in:

press release

Sept. 25, 2020, 9:00 a.m. EDT

Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors

Frequency Therapeutics, Inc. /zigman2/quotes/214411420/composite FREQ -2.29% , a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Directors.

Ms. Feldmann is an experienced finance and accounting professional who brings to Frequency several decades of experience in life sciences and public company board leadership. She was formerly a partner at KPMG LLP, where she held leadership roles in the firm’s medical technology and health care and life sciences industry groups, and was the lead partner in the life sciences practice for Coopers & Lybrand (now PricewaterhouseCoopers LLP) during her 19-year career there. Currently, she is a member of the board of directors at STERIS PLC /zigman2/quotes/203973646/composite STE +0.91% and at UFP Technologies /zigman2/quotes/203675725/composite UFPT -0.02% .

“Cynthia’s financial expertise and deep public board experience will be of tremendous value to our organization as we continue to scale Frequency,” said David L. Lucchino, Frequency’s chief executive officer. “We look forward to her contributions as we work to advance a therapy to potentially treat the millions of people with hearing loss and move toward development of our remyelination program for patients with multiple sclerosis.”

“I am thrilled to join Frequency’s board and to be part of a company working to solve such a profoundly complex challenge as hearing restoration,” said Ms. Feldmann. “I have been deeply impressed both with the strength and vision of leadership, the commitment of the team to pursue this audacious objective and their focus on building a world-class research and development organization. It’s exciting to join the company at this time to be part of something so potentially groundbreaking.”

Ms. Feldmann has served on the STERIS board for more than fifteen years and chaired its audit committee for eight years. She has also been a director at Atrius Health, Hanger Inc. /zigman2/quotes/201464689/composite HNGR +0.21% , a provider of orthotic and prosthetic services and products and Heartware International, Inc., a medical device company that was acquired by Medtronic.

“Cynthia is a great addition and will provide tremendous perspective having worked as an independent board member for newly-public companies and contributing to their success over time,” said Marc A. Cohen, chairman of the board of directors at Frequency Therapeutics. “Her breadth of experience will further strengthen the organization, and I look forward to her partnership during this important time for the company and its growth.”

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In an FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in an ongoing Phase 2a clinical study in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Cambridge Enterprises Limited (the commercialization arm of the University of Cambridge), Massachusetts Eye and Ear, Mass General Brigham and the Massachusetts Institute of Technology. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200925005055/en/

SOURCE: Frequency Therapeutics, Inc.

Investor:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
617-914-0008 Media:
Suzanne Day
Frequency Therapeutics
sday@frequencytx.com
781-496-2211

COMTEX_371857262/2456/2020-09-25T09:00:22

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2020

/zigman2/quotes/214411420/composite
US : U.S.: Nasdaq
$ 9.80
-0.23 -2.29%
Volume: 756,327
April 15, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$342.80 million
Rev. per Employee
$425,103
loading...
/zigman2/quotes/203973646/composite
US : U.S.: NYSE
$ 206.71
+1.87 +0.91%
Volume: 861,016
April 15, 2021 4:00p
P/E Ratio
41.07
Dividend Yield
0.77%
Market Cap
$17.48 billion
Rev. per Employee
$233,146
loading...
/zigman2/quotes/203675725/composite
US : U.S.: Nasdaq
$ 49.99
-0.01 -0.02%
Volume: 50,264
April 15, 2021 4:00p
P/E Ratio
28.24
Dividend Yield
N/A
Market Cap
$376.00 million
Rev. per Employee
$177,597
loading...
/zigman2/quotes/201464689/composite
US : U.S.: NYSE
$ 24.20
+0.05 +0.21%
Volume: 75,307
April 15, 2021 4:00p
P/E Ratio
24.69
Dividend Yield
N/A
Market Cap
$930.49 million
Rev. per Employee
$213,011
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.